A Phase I Study of Vincristine, Irinotecan, Temozolomide and Bevacizumab (Vitb) in Pediatric Patients with Relapsed Solid Tumors

Rajkumar Venkatramani,Marcio H. Malogolowkin,Tom Davidson,William A. May,Richard Sposto,Leo Mascarenhas

A Phase I Study of Vincristine, Irinotecan, Temozolomide and Bevacizumab (Vitb) in Pediatric Patients with Relapsed Solid Tumors

2013

Rajkumar Venkatramani
Marcio H. Malogolowkin
Tom Davidson
William A. May
Richard Sposto
Leo Mascarenhas

Background To determine the maximum tolerated dose (MTD) and dose limiting toxicity (DLT) of irinotecan administered in combination with vincristine, temozolomide and bevacizumab in children with refractory solid tumors.

Keywords:

Temozolomide
Oncology
Refractory
Bevacizumab
Vincristine
Irinotecan
Radiation therapy
Dacarbazine
Camptothecin
Pharmacology
Medicine
Internal medicine
Medulloblastoma
Surgery
Gastroenterology
Toxicity

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations